BioSenic fait le point sur ses activités du premier trimestre 2023
May 22, 2023 01:00 ET
|
BioSenic
INFORMATION RÉGLEMENTÉE Résultats principaux ALLOB Phase IIb prévus en Juillet/Août 2023 Discussions en cours en vue de partenariats clés pour les actifs cliniques avancés Mont-Saint-Guibert,...
Jasper Therapeutics Announces Appointment of Stephen J. Galli, M.D. to Scientific Advisory Board
May 10, 2023 08:00 ET
|
Jasper Therapeutics
REDWOOD CITY, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy...
Tonix Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Highlights
May 08, 2023 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Prioritizing Late-Stage Clinical CNS Programs in Fibromyalgia, Depression, Migraine, and Cocaine Intoxication Topline Results Expected in Fourth Quarter 2023 for Potentially Confirmatory Phase 3...
Tonix Pharmaceuticals Announces IND Clearance for TNX-1500 (anti-CD40L mAb) for the Prevention of Organ Rejection in Patients Receiving a Kidney Transplant
May 04, 2023 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Multiple Additional Indications Possible, Including Autoimmune Diseases: Pipeline within a Product Published Non-Human Primate Studies Show TNX-1500 Prolongs Renal and Heart Allograft Survival Phase...
Lumos Pharma Reports First Quarter 2023 Financial Results, Provides Clinical Updates
May 03, 2023 16:05 ET
|
Lumos Pharma, Inc.
-- Patient Enrollment Completed in both Phase 2 OraGrowtH Trials ---- Primary Outcome Data for both OraGrowtH Trials Expected 4Q 2023 ---- Interim Data from OraGrowtH Trials Accepted for Presentation...
BioSenic publie ses résultats annuels 2022
April 27, 2023 01:00 ET
|
BioSenic
INFORMATION RÉGLEMENTÉE Résultats finaux ALLOB Phase IIb prévus au T2 2023 Lancement de ATO Phase III prévu en 2023 Discussions en cours en vue de partenariats clés pour les actifs cliniques...
Tonix Pharmaceuticals Announces Two Publications of Data in American Journal of Transplantation Showing TNX-1500 (anti-CD40L mAb) Prolongs Nonhuman Primate Renal and Heart Allograft Survival
April 17, 2023 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., April 17, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced the on-line publication of two...
Arbor Biotechnologies Appoints Dr. Daniel Ory as Chief Medical Officer
April 12, 2023 07:00 ET
|
Arbor Biotechnologies Inc
CAMBRIDGE, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic editing medicines, today announced the...
Denali Therapeutics Announces New DNL343 (eIF2B Agonist) Phase 1b Data in ALS To Be Presented at the Upcoming AAN Annual Meeting
April 10, 2023 08:00 ET
|
Denali Therapeutics Inc.
Data show that DNL343 is generally well-tolerated at doses that demonstrate robust inhibition of biomarkers associated with the integrated stress response (ISR)Clinical pharmacokinetic and ISR...
The Global Electronic Stability Control Market size is expected to reach $13.6 billion by 2028, rising at a market growth of 8.0% CAGR during the forecast period
March 23, 2023 07:56 ET
|
ReportLinker
New York, March 23, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Electronic Stability Control Market Size, Share & Industry Trends Analysis Report By...